Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01518634
Other study ID # 2011-004294-87
Secondary ID
Status Completed
Phase Phase 2
First received January 13, 2012
Last updated May 8, 2017
Start date January 2012
Est. completion date December 2016

Study information

Verified date June 2016
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to test the effect of the tricyclic antidepressant Imipramine in patients with longlasting health problems with no known medical explanation, defined as multi-organ Bodily distress syndrome (BDS). Pharmacological treatment of patients with BDS have never been tested, and Imipramine i low dosage (10-75 mg) has the potential of reducing both pain and other symptoms of bodily distress for patients with BDS. Control conditions are pill placebo. Study duration is 19 weeks for each of the 140 patients. End point is 13 weeks, i.e. after 10 weeks of 25-75 mg study drug.


Description:

The aim of this study is to test the effect of Imipramine in patients with multi-organ Bodily distress syndrome (BDS). BDS is a unifying diagnosis that encompasses a group of closely related conditions such as somatization disorder, fibromyalgia, irritable bowel syndrome and chronic fatigue syndrome. The project consists of a double-blinded placebo controlled trial of treatment with the tricyclic antidepressant Imipramine in dosages of 25-75 mg. Primary outcome is patient-rated improvement measured by Clinical Global Improvement Scale (CGI-I). Secondary outcome is functional level (physical, mental and social) measured by the SF-36 Physical Component Summary (PCS). The study requires 140 participants and study duration is 19 weeks for each patient. End point is 13 weeks, i.e. after 10 weeks of 25-75 mg study drug.


Recruitment information / eligibility

Status Completed
Enrollment 138
Est. completion date December 2016
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender All
Age group 20 Years to 50 Years
Eligibility Inclusion Criteria:

1. First time refered patients fulfilling diagnostic criteria for BDS multi-organ type with symptoms for more than 3 of 4 symptom categories

2. Moderate or severe impact on daily life

3. Symptoms lasting for at least 2 years

4. Age 20-50 years

5. Born in Denmark or have Danish parents. The patient understands, speaks, writes and read Danish.

Exclusion Criteria:

1. Presence og other physical of psychiatric condition, if the symptoms of this condition can not clearly be separated from symptoms of BDS

2. Current moderate or severe depression, patients in continuous antidepressant treatment because of moderate or severe depression, and patients with other severe psychiatric disorder that demands treatment, or if the patient is suicidal.

3. A lifetime-diagnosis of psychoses, mania or depression with psychotic symptoms (ICD-10: F20-29, F30-31, F32.3, F33.3)

4. Abuse of alcohol, narcotics or drugs

5. Pregnancy, breastfeeding or current pregnancy wish. Fertile women must use effective anticonception, (hormonal contraception, contraceptive injection, implant or patches, intrauterine system and device, vaginal ring).

6. Treatment with all pain modulating drugs, e.g. all analgesics, antidepressants, antiepileptica and other types of medication with pain relieving properties must be discontinued at least two weeks before the treatment phase.

7. Imipramine treatment in sufficient dosage within the last year, i.e. 25 mg daily continuously for at least 8 weeks.

8. Allergy to study medication or excipients in study medication.

9. Patients with previous med myocardial infarction, congestive heart failure, signs of conduction defects or abnormalities on ECG (first degree AV-block, bundle branch block or prolonged QT-interval), narrow-angle glaucoma, porphyria, inherited galactose intolerance, epilepsy, hepatic insufficiency and severe renal impairment

10. Simultaneous use of:

- antipsychotics

- oral anticoagulants

- diuretics

- sympathomimetics and CNS-stimulating drugs (amphetamine-like drugs)

- all serotonergic drugs, e.g. SSRI, SNRI and TCA, the dietary supplement hypericum perforatum, non-selective, irreversible or selective, reversible monoamine oxidase (MAO) inhibitors, triptans, tramadol, pethidin and tryptophan

- the drugs cimetidine (H2-antagonist), quinidine (antiarrythmics), clonidine (antihypertensive), fluconazol (antimycotics), clindamycin, clarithromycin, erythromycin (antibiotics), droperidol (anaesthetic), levodopa (antiparkinson), mefloquine (antimalaria), phenytoin, barbiturates, carbamazepin (antiepileptica)

- Bupropion (tobacco dependence), celecoxib (NSAID), cinacalcet (antiparathyroid drug), duloxetine (SNRI), flufenazin (antipsychotic), fluoxetin (SSRI), gefitinib (antineoplastic), moclobemid (MAO), paroxetine, Sertraline (SSRI), Terbinafine (antimycotics), Yohimbin (erectile dysfunction) samt fluvoxamin (SSRI), ciprofloxacin and enoxacin (microbiotic), because plasma concentration of Imipramine can increase with the simultaneous use of these potent CYP2D6- and CYP1A2- inhibitors

Study Design


Intervention

Drug:
Imipramine treatment
Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
Placebo
Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.

Locations

Country Name City State
Denmark Research Clinic for Functional Disorders Aarhus

Sponsors (1)

Lead Sponsor Collaborator
University of Aarhus

Country where clinical trial is conducted

Denmark, 

References & Publications (1)

Agger JL, Schröder A, Gormsen LK, Jensen JS, Jensen TS, Fink PK. Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study. Lancet Psychiatry. 2017 May;4(5):378-388. doi: 10.1016/S2215-0366(17)30126-8 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Global Clinical Improvement Scale Questionnaire, patient-rated improvement of health since the beginning of the study. After 13 weeks
Secondary SF-36 Questionnaire, patient-rated. Assessment of physical, social and mental functioning At 1 and 13 weeks
Secondary Visual Analogue Scale for pain and worst symptom At 1 and 13 weeks
Secondary Symptom Checklist (SCL) At 1, 3 and 13 weeks
Secondary Functional Illness Checklist (FIC) At 1, 3 and 13 weeks
Secondary WHODAS II At 1 and 13 weeks
See also
  Status Clinical Trial Phase
Completed NCT00276887 - Cognitive Behavior Therapy for Somatization Disorder Phase 2
Enrolling by invitation NCT05565352 - Observation of Ketamine Treatment Safety and Tolerability in Adult Psychiatry Clinic Medical University of GdaƄsk Inpatients
Active, not recruiting NCT04847310 - Cost-benefit Evaluation of a Transdiagnostic Psychological Treatment for Emotional Disorders in Primary Care N/A
Completed NCT05611606 - Welfare Benefits in Functional Somatic Disorders
Completed NCT05631860 - Psychological Risk Factors for Functional Somatic Disorders
Completed NCT02151500 - Stress and Health Interview for Primary Care Patients With Medically Unexplained Symptoms N/A
Completed NCT01590992 - Treatment of Globus Sensations With Psychotherapy N/A
Completed NCT00149799 - Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder Phase 3
Completed NCT00368212 - Integrated Treatment Program for Hypochondriasis in Primary Care Settings Phase 3
Terminated NCT02843932 - Subjective Perception of Motor Control During Psychogenic Disorders N/A
Terminated NCT03904784 - School Withdrawal in Adolescents
Recruiting NCT04807933 - Neurovegetative Decoupling in Somatoform Disorders : Biofeedback Interest N/A
Completed NCT01119469 - Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis Phase 3
Recruiting NCT03188861 - Systematic Screening for Comorbid Psychological Conditions in Cardiac ACSC Patients With Multimorbidity in the ED
Recruiting NCT04835103 - Build a Research Clinic for Somatoform Patients N/A
Completed NCT02346071 - Acceptance and Commitment Group Therapy for Adolescents With a Range of Functional Somatic Syndromes N/A
Completed NCT01518647 - Acceptance and Commitment Therapy for Patients With Multi-organ Bodily Distress Syndrome (Stress-4) N/A
Recruiting NCT01391897 - Epigenetics of Posttraumatic Stress Disorder and Somatoform Disorders in the Course of Psychotherapy N/A
Completed NCT01924715 - Evaluating the Cost Effectiveness of ISTDP: A Quasi Experimental Study N/A
Completed NCT00130988 - DEPENAS: A Psychosocial Intervention for Patients With Medically Unexplained Symptoms Phase 3